SCHEMBL5319646

SCHEMBL5319646

O=C(O)CCc1nn(Cc2ccc(Cl)cc2Cl)c2cc(OC(F)(F)F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.49
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
PMP22 Q01453 1/20 0.45
HIF1A Q16665 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
SLC22A12 Q96S37 2/20 0.43
KMO O15229 1/20 0.41
NPC1 O15118 1/20 0.41
EPHX2 P34913 2/20 0.41
SLC16A3 O15427 3/20 0.40
SLC16A1 P53985 3/20 0.40
MCTS1 Q9ULC4 3/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PLA2G10 O15496 1/20 0.40
PLA2G2A P14555 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316023 0.95 PPARG (0.46) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5317632 0.92 SLC22A12 (0.42) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5316549 0.92 SLC22A12 (0.42) PPARGCYP2C9SLC22A12KMOPTGDR2
SCHEMBL5316539 0.91 KMO (0.44) PPARGCYP3A4CYP2C9SLC22A12KMO
SCHEMBL12520320 0.90 PTGDR2 (0.48) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5323336 0.88 TRPV1 (0.42) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5323485 0.87 FFAR4 (0.42) PPARGCYP2C9SLC22A12KMOPTGDR2
SCHEMBL5322288 0.87 FFAR4 (0.41) PPARGCYP3A4CYP2C9SLC22A12SLC16A3
SCHEMBL998580 0.87 PPARG (0.56) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5317597 0.87 TRPV1 (0.41) PPARGCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP claimed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP disclosed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO disclosed